On April 27, 2021 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported that it will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) (Free ASGCT Whitepaper) meeting (Press release, Adaptimmune, APR 27, 2021, View Source [SID1234578551]). Abstracts were published online today, and data will be updated during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: In vitro selection and engineering of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin (Abstract # 641)
Poster Presentation: Tuesday May 11, 2021 8:00 a.m. – 10:00 a.m. EDT during the Cancer – Immunotherapy, Cancer Vaccines Session